Raven StealthCo- Director/Senior Director, Biology

Benefits

Additional Information

About Raven: We are Raven, RA Capital's healthcare incubator. From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven's goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most. Raven's experienced scientists, operators, and healthcare innovators have deep sector expertise across therapeutics, diagnostics, devices and services. They have brought hundreds of therapeutics into development, managed hospital systems, optimized clinical trials and navigated payor and regulatory systems to deliver patient impact - and they are ready to work with you. About RA Capital: Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital's company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management. Company Background We are a well-funded, stealth-mode biotechnology company developing next-generation oligonucleotide-based therapeutics for a high-value disease area with significant unmet medical need. The company is headquartered in Cambridge, Massachusetts, and was incubated and funded by a leading life sciences venture group. We are led by an experienced founder-CEO with a strong track record of building and scaling biotechnology companies. The company has completed a robust incubation process and is backed by a substantial seed investment. Our disease focus represents a large, multi-billion-dollar market with significant room for improvement over existing therapies. We are building a first-of-its-kind integrated platform leveraging tailored oligonucleotide chemistry, targeted delivery, and state-of-the-art analytics to develop first-in-class and best-in-class therapeutics. The company is currently operating in stealth mode as we commit to building and scaling quickly to create transformational medicines with significant market potential. Our platform is designed to address multiple disease indications at scale, including both primary and adjacent therapeutic areas. Opportunity The company is in the discovery stage and will invest heavily in its emerging platform for oligonucleotide delivery. Our disease focus offers strong translatability from animal models to humans, which provides a potentially rapid and efficient path to the clinic. Given the company's recent funding and commitment to building a first-in-class platform with clear therapeutic targets and indications, we are recruiting a Principal Scientist, Analytical Chemistry. This individual will be responsible for developing analytical methods and characterizing our oligonucleotide conjugates for our targeted delivery platform. The Position The Senior Director/Director Biology will report directly to the Head of Research/CSO. This individual will work closely with cross-functional leaders to translate the delivery platform into therapeutic programs with deep biological insights. The Senior Director/Director will hold a key position in formulating and implementing the scientific strategy for development of our disease biology platform from in vitro assays to in vivo pre-clinical pharmacology in various models and species, as well as in recruiting, mentoring, and coaching the skilled scientific team under their leadership. Specific responsibilities for the Senior Director/Director Biology include: ● Build a research team of 3 while strategically leveraging consultants and CROs to accelerate early-stage discovery ● Lead a deep understanding of initial indication area biology by developing relationships with KOLs and extending further insights into the MOA of lead target(s) utilizing physiological and next-generation "omic" measurement tools ● Synthesize large datasets alongside mechanistic insights in cell biology and physiology to identify and prioritize novel targets actionable via company's platform ● Develop and own the suite of in vitro and in vivo assays needed for lead indication biology, including endpoint measurements for target manipulation across relevant cell types ● Lead and manage CRO partnerships supporting in vivo pharmacology, including design and evaluation of readouts across relevant disease models ● Collaborate with the VP of Delivery to analyze the biodistribution and pharmacodynamic metrics of the delivery platform, including assessments of proximal oligonucleotide effects on target genes (e.g. IHC, spatial tr

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at raven? Share your experience